质子泵抑制剂是一种新型降糖药物吗？一项横断面研究。
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study.
机构信息
Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo Trincado- Aznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain.
出版信息
World J Diabetes. 2011 Dec 15;2(12):217-20. doi: 10.4239/wjd.v2.i12.217.
AIM
To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients.
METHODS
A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010 who had a recent HbA1c measurement. The study excluded those with a diagnosis of hyperglycemic decompensation, diabetic onset or pregnancy. It compared HbA1c levels of those taking PPIs and those not.
RESULTS
A total of 97 patients were recruited. The average HbA1C level was 7.0% ± 1.2%. Overall PPI consumption was 55.7%. HbA1c was significantly lower in individuals who took PPIs: -0.6%, 95% CI: -0.12 to -0.83. People who used PPIs with some type of insulin therapy had a HbA1c reduction by -0.8%, 95% CI: -0.12 to -1.48. For the rest of subgroup analysis based on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels.
CONCLUSION
PPIs seems to be consistently associated with better glycemic control in type 2 diabetes. HbA1c reduction observed is similar to incretin-based therapies.
目的
研究质子泵抑制剂（PPIs）对 2 型糖尿病患者血糖控制（HbA1c）的影响。
方法
这是一项 2010 年上半年在医院任何科室住院的连续患者的横断面研究，这些患者最近进行了 HbA1c 测量。该研究排除了高血糖失代偿、糖尿病发病或妊娠的患者。它比较了服用 PPI 和未服用 PPI 的患者的 HbA1c 水平。
结果
共招募了 97 名患者。平均 HbA1C 水平为 7.0%±1.2%。总体 PPI 使用率为 55.7%。服用 PPI 的个体的 HbA1c 明显降低：-0.6%，95%CI：-0.12 至-0.83。使用 PPI 联合某种胰岛素治疗的患者 HbA1c 降低了-0.8%，95%CI：-0.12 至-1.48。对于基于使用的抗糖尿病药物的其余亚组分析，PPI 消耗始终表现出较低的 HbA1c 水平。
结论
PPI 似乎与 2 型糖尿病的血糖控制改善始终相关。观察到的 HbA1c 降低与肠促胰岛素治疗相似。
Zotero 插件